Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-21 (canceled).

22 (currently amended). A method of treating ~~infections~~ an infection of the lower respiratory tract, ~~in a human or animal~~ comprising administering to a patient in need thereof an amount of liposomes sufficient to treat the infection, ~~a pharmaceutical preparation to the lower respiratory tract~~, said liposomes containing ~~preparation comprising inhalable liposomes combined with~~ povidone iodine.

Claims 23-31 (canceled).

32 (currently amended). The method according to claim 22 ~~or 23~~, wherein the liposomes have a ~~size~~ diameter in the range ~~between~~ from about 1 μm ~~and~~ to about 50 μm.

33 (currently amended). The method according to claim 32, wherein the liposomes have a ~~size~~ diameter in the range ~~between~~ from 20 μm to ~~and~~ 30 μm ~~diameter for application to the trachea~~.

Claims 34-35 (canceled).

36 (currently amended). The method of claim 22 ~~or 23~~, wherein the liposomes ~~preparation additionally~~ further contain an ~~comprises at least one~~ anesthetically active agent.

37 (currently amended). The method of claim 22 ~~or 23~~, wherein the liposomes ~~preparation~~ further ~~comprises~~ contain a pharmaceutically acceptable additive ~~additives~~.

38 (currently amended). The method of claim 22 ~~or 23~~, wherein the ~~liposomes are suitable for~~ administration is by inhaling the liposomes ~~via nebulization or aerosolization~~.

39 (currently amended). The method of claim 22 ~~or 23~~, wherein the ~~preparation comprises~~ liposomes are in the form of ~~a tablet, a gelatin capsule,~~ a powder, a spray, an emulsion or a dispersion ~~containing the liposomes and povidone iodine in a pharmaceutically acceptable solid or liquid formulation, which is suitable for the generation of inhalable particles~~.

40 (currently amended). The method of claim ~~22~~ 32, wherein said ~~preparation comprises:~~

~~(a) comprising a pharmaceutically acceptable liposome membrane forming substance; and~~

~~(b)~~ liposomes contain between 0.1 to 10%, by weight, povidone ~~PVP~~ iodine~~, wherein the liposomes are in a size between about 1 μm and about 50 μm~~.

41 (currently amended). The method of claim 40, wherein the liposomes have a diameter in the ~~are in a size~~ range ~~between~~ from 20 μm ~~and~~ to 30 μm ~~diameter for application to the treachea~~.

Claims 42-50 (canceled).

51 (currently amended). The method of claim 22 ~~or 23~~, wherein the liposomes have a diameter ~~size~~ in the range ~~between~~ from about 1 μm to ~~and~~ 30 μm.

Claims 52-54 (canceled).

55 (currently amended). The method of claim 22 ~~or 23,~~ wherein the liposomes have a diameter ~~size~~ in the range ~~between~~ from 10 μm ~~and~~ to 20 μm ~~diameter for application to the bronchi~~.

56 (currently amended). The method of claim 22, wherein the liposomes have a diameter ~~size~~ in the range ~~between~~ from 1 μm ~~and~~ to 6 μm ~~diameter for application to the alveoli~~.

57 (currently amended). The method of claim 22, wherein the liposomes have a diameter ~~size~~ in the range ~~between~~ from 2 μm ~~and~~ to 5 μm ~~diameter for application to the alveoli~~.

58 (currently amended). The method of claim 22 ~~preparation of claim 17~~, wherein said liposomes comprise a liposome membrane forming substance that is present in an amount between 1 to 5%, by weight, of the liposomes ~~preparation~~.

59 (currently amended). The method of claim 22 ~~preparation of claim 17~~, wherein said liposomes are ~~liposome membrane forming substance comprises~~ lecithin liposomes.

60 (currently amended). The method of claim 40, wherein said liposomes comprise a liposome membrane forming substance that is present in an amount between about 1 to 5%, by weight, of the ~~preparation~~ liposomes.

61 (currently amended). The method of claim 40, wherein said liposomes are ~~liposome membrane forming substance comprises~~ lecithin liposomes.

Claims 62-63 (canceled).

64 (new). The method of claim 40, wherein said liposomes contain about 0.1% to 2% by weight of povidone iodine.

65 (new). The method of claim 22, wherein the infection is in the treachea.

66 (new). The method of claim 22, wherein the infection is in the bronchi.

67 (new). The method of claim 22, wherein the infection is in the alveoli.

68 (new). The method of claim 22, wherein the liposomes further contain a corticosteroid.

69 (new). The method of claim 22, wherein the liposomes further contain a second antiseptic agent.

70 (new). The method of claim 69, wherein said second antiseptic agent is an oxygen-releasing compound, a halogen-releasing compound, a silver compound, a mercury compound, a formaldehyde-releasing compound, an alcohol, a phenol, a quinoline, an acridine, a hexahydropyrimidine, a quaternary ammonium compound, or a guanidine.

71 (new). The method of claim 22, wherein the liposomes further contain an antibiotic.

72 (new). The method of claim 22, wherein said liposomes further contain dexpanthenol, an allantoine, an azulene, a tannine, or a vitamin B compound.

73 (new). The method of claim 22, wherein the infection is a bacterial, fungal, or viral infection.

74 (new). The method of claim 22, wherein the patient is human.